MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide): Gold Standard Tetrazolium Salt for Cell Viability Assays

Executive Summary: MTT is a yellow tetrazolium salt broadly used to quantify cell viability and metabolic activity in vitro (APExBIO, product page). Viable cells reduce MTT to purple formazan crystals via NADH-dependent mitochondrial and extra-mitochondrial enzymes, correlating with live cell number [1]. The assay is highly sensitive, reproducible, and adaptable across cancer, apoptosis, and metabolic studies [2]. MTT is membrane-permeable and cationic, allowing efficient cellular uptake without intermediates. APExBIO provides high-purity MTT (≥98%) for research use, with validated solubility and protocol guidance [3].

Biological Rationale

Cell viability and proliferation assays are central to biomedical research, informing studies of cancer, apoptosis, drug cytotoxicity, and metabolic regulation. Tetrazolium salts are preferred reagents for quantifying viable cells because they are reduced only by metabolically active cells, providing a direct readout of cell health [4]. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) is the most widely adopted first-generation tetrazolium salt for these purposes. Its reduction to formazan is driven by cellular NAD(P)H-dependent oxidoreductases, reflecting both mitochondrial and extramitochondrial metabolic activity [2]. Because MTT is cationic and membrane-permeable, it can enter intact cells efficiently without the need for transporters or permeabilizing agents [1]. This enables robust, high-sensitivity quantification of living cells in diverse experimental setups.

Mechanism of Action of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide)

MTT is reduced from a yellow, water-soluble tetrazolium compound to insoluble purple formazan crystals within viable cells. This reduction is catalyzed primarily by NADH-dependent mitochondrial enzyme systems (notably succinate dehydrogenase), as well as other oxidoreductases in the cytosol and plasma membrane [5]. The resulting formazan accumulates intracellularly and can be solubilized using DMSO, ethanol, or water (with ultrasound) for spectrophotometric quantification at 570 nm [3]. The amount of formazan produced is directly proportional to the number and metabolic activity of viable cells, enabling quantitative assessment of cell viability, proliferation, or cytotoxicity. MTT does not require exogenous electron carriers, distinguishing it from second-generation, negatively charged tetrazolium salts that depend on intermediate electron acceptors [2].

Evidence & Benchmarks

• MTT reduction is strictly dependent on cellular metabolic activity; dead cells do not reduce MTT to formazan (cell-staining-kit.com).
• Formazan production correlates linearly with viable cell number over a wide dynamic range, supporting accurate quantification (btz043.com).
• MTT is soluble at ≥41.4 mg/mL in DMSO, ≥18.63 mg/mL in ethanol, and ≥2.5 mg/mL in water (ultrasound-assisted), facilitating flexible assay design (apexbt.com).
• MTT is stable when stored at -20°C; aqueous solutions should be freshly prepared and used short-term to avoid decomposition (apexbt.com).
• CRISPR/Cas9 knockout of ABCB1 in multidrug-resistant cancer cells was validated using MTT assays to quantify increased sensitivity to chemotherapeutics (Am J Transl Res 2016;8(9):3986-3994, source).
• MTT is a benchmark for in vitro cell proliferation and metabolic activity, with robust workflows established across cancer, neurobiology, and drug discovery (apoptosis-kit.com).

Applications, Limits & Misconceptions

MTT is indispensable in cancer research, apoptosis assays, drug cytotoxicity studies, and metabolic profiling [6]. Its compatibility with 96-well and 384-well microplate formats enables high-throughput screening. The assay is adaptable to adherent and suspension cells from multiple species. However, MTT reduction strictly measures metabolic activity—not direct cell count or specific cell death mechanisms. Some cell types or treatments can alter metabolic flux without affecting viability, potentially confounding results.

Common Pitfalls or Misconceptions

• MTT does not distinguish apoptosis from necrosis: Both processes can reduce metabolic activity, but MTT cannot specify the cell death pathway.
• Interfering substances: Reducing agents, high serum concentrations, or colored compounds in the media may interfere with absorbance readings or MTT reduction.
• Dead cells are not detected: MTT measures only metabolically active cells; non-viable cells yield no signal.
• MTT is not suitable for in vivo imaging: Due to formazan insolubility and lack of tissue penetration, MTT is limited to in vitro applications.
• Prolonged incubation or delayed solubilization may alter results: Formazan can diffuse or aggregate, leading to under- or overestimation of cell viability.

Workflow Integration & Parameters

MTT (B7777) from APExBIO is supplied at high purity (≥98%), ensuring batch-to-batch consistency. Recommended storage is at -20°C to maintain stability. For routine assays, dissolve MTT at ≥41.4 mg/mL in DMSO for stock solutions; dilute in culture medium to 0.5–1 mg/mL for cell exposure. Incubate cells with MTT for 2–4 hours at 37°C in 5% CO₂. After incubation, remove medium and solubilize formazan with DMSO, ethanol, or water (ultrasound-assisted). Measure absorbance at 570 nm (reference: 630–690 nm) for optimal linearity. Follow detailed protocols and troubleshooting strategies in this guide, which expands on advanced troubleshooting and protocol optimization beyond the scope of this article.

This article extends prior reviews by integrating updated storage, solubility, and mechanistic details, as well as clarifying distinctions with second-generation tetrazolium salts [1]. For advanced neuroinflammation and apoptosis applications, see this overview, while our current focus emphasizes metabolic and cancer research benchmarking.

Conclusion & Outlook

MTT remains the gold standard for colorimetric cell viability and metabolic activity measurement. Its rapid, sensitive, and quantitative readout supports diverse research applications in cancer biology, apoptosis, and drug discovery. APExBIO’s MTT (B7777) offers high purity and validated performance, with robust inter-assay reproducibility and flexible protocol options. Future advances in multiplexing and high-throughput automation will further expand MTT’s utility in preclinical and translational workflows. For authoritative protocols and product details, visit the APExBIO MTT product page.